



The Breast Cancer Research Foundation Renews Commitment to OnPAR

Reston, Va., [September 6, 2017] – The Breast Cancer Research Foundation (BCRF) will renew its subscription to [OnPAR](#), the Online Partnership to Accelerate Research. Developed by Leidos, OnPAR provides innovative and exceptional research applications with a second opportunity for funding.

Globally approximately 85 percent of the research applications submitted to government funding agencies go unfunded, leaving an innovation gap that may stifle research discovery and delay discoveries that could advance potential treatments and cures for many diseases. OnPAR is expanding globally to offer a new funding paradigm with the goal of matching highly scored, unfunded fully peer-reviewed applications with potential non-government organizations.

BCRF's mission is to prevent and cure breast cancer by advancing the world's most promising research. BCRF provides critical funding for cancer research worldwide to fuel advances in tumor biology, genetics, prevention, treatment, metastasis and survivorship.

"We're proud to continue our relationship with BCRF," says Leidos Health Group President Jon Scholl. "OnPAR presents BCRF with high-quality research applications with the potential to accelerate research discoveries, treatments and potential cures for breast cancer."

Any funding organization interested in becoming a member can find more information on the OnPAR website at <https://onpar.leidosweb.com>. Please visit OnPAR frequently for further announcements and join us in our effort to accelerate research and find treatments and potential cures for the many diseases affecting our communities.

About Leidos

Leidos is a Fortune 500® science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately \$7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com.

About BCRF

BCRF funds research on (1) Heredity & Ethnicity, (2) Lifestyle & Prevention, (3) Metastasis, (4) Survivorship, (5) Treatment, and (6) Tumor Biology. Breast cancer is a complex disease with no simple solution. That's why BCRF researchers are tackling it from every angle. Learn more about BCRF [here](#)